Pipeline Novartis gets win for another Avidity muscular dystrophy AOC PharmaphorumNovartis' $12bn takeover of Avidity could potentially give it the first therapy for genetic disorder facioscapulohumeral muscular dystrophy.Rare DiseaseRead full story pharminent June 11, 2026 (Last updated: June 11, 2026) Pharmaphorum Novartis’ $12bn takeover of Avidity could potentially give it the first therapy for genetic disorder facioscapulohumeral muscular dystrophy. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: SonoThera bags $125M series B to advance safer gene therapiesNext: J&J adds rare disease wAIHA to Imaavy’s potential uses Related Stories Pipeline Sanofi drops two more programmes in R&D clear-out pharminent July 30, 2026 Pipeline Lundbeck preps for key bexicaserin data around year-end pharminent July 20, 2026 Pipeline AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist pharminent July 10, 2026
